Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study

Fig. 2

Change in average pain in the index joint. LS mean (SE) changes, from baseline, in average pain in the index joint scores are shown over the first 7 days (A) and full 56 weeks (B) of treatment. *Unadjusted p ≤ 0.05 for tanezumab 2.5mg versus NSAID. +Unadjusted p ≤ 0.05 for tanezumab 5mg versus NSAID. LS, least squares; NSAID, nonsteroidal anti-inflammatory drug; SE, standard error

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us